MondegarAI
SILVERARC CAPITAL MANAGEMENT, LLC

Q4 2024 · 13F-HR

SILVERARC CAPITAL MANAGEMENT, LLCholdings as filed

Filed 2025-02-14 · accession 0001420506-25-000497

$457.2M
Reported value
61
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
670703107NUVLNUVALENT INC$31.3M6.85%400,014CommonSOLE
N5749R1002GHMERUS N V$28.6M6.26%680,845CommonSOLE
457669307INSMINSMED INC$25.7M5.62%372,230CommonSOLE
925050106VRNAVERONA PHARMA PLC$24.0M5.24%516,014CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$20.6M4.50%739,563CommonSOLE
92337F107VCYTVERACYTE INC$19.9M4.36%503,281CommonSOLE
29479A108ERASERASCA INC$18.9M4.14%7,543,901CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$17.3M3.79%1,315,601CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$16.3M3.56%1,230,400CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$15.8M3.46%543,651CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$15.3M3.35%273,896CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC$15.0M3.27%179,085CommonSOLE
M96088105URGNUROGEN PHARMA LTD$11.9M2.61%1,120,473CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$10.0M2.19%598,952CommonSOLE
50015M109KODKODIAK SCIENCES INC$9.9M2.18%1,000,000CommonSOLE
73730P108PSTXUSDPOSEIDA THERAPEUTICS INC$9.7M2.13%1,012,307CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$9.5M2.08%1,178,300CommonSOLE
872381108TELATELA BIO INC$9.3M2.03%3,065,649CommonSOLE
80706P103SRRKSCHOLAR ROCK HLDG CORP$7.9M1.73%183,243CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$7.5M1.65%608,897CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$7.2M1.57%921,137CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$7.1M1.55%51,491CommonSOLE
254604101IRONDISC MEDICINE INC$7.0M1.53%110,381CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$6.7M1.46%264,560CommonSOLE
05479K106ELUTELUTIA INC$6.7M1.46%1,782,271CommonSOLE
09075X108BIODESIX INC$6.6M1.45%4,332,281CommonSOLE
00973Y908AKERO THERAPEUTICS INC$6.1M1.34%220,000CALLSOLE
38341P102GOSSGOSSAMER BIO INC$5.6M1.22%6,171,847CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$5.6M1.22%72,516CommonSOLE
G4444H101BBOTHELIX ACQUISITION CORP II$5.4M1.18%513,369CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL IN$5.2M1.14%124,388CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$5.2M1.13%612,173CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$4.8M1.06%277,365CommonSOLE
12529R107CCCCC4 THERAPEUTICS INC$4.4M0.96%1,221,131CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$4.1M0.90%152,395CommonSOLE
87650L103TARSTARSUS PHARMACEUTICALS INC$3.7M0.80%65,955CommonSOLE
45337C102INCYINCYTE CORP$3.4M0.74%49,000CommonSOLE
92243G108PCVXVAXCYTE INC$3.3M0.73%40,788CommonSOLE
374163103GERNGERON CORP$3.3M0.71%920,022CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$3.0M0.66%734,234CommonSOLE
M25722105CGENCOMPUGEN LTD$2.5M0.54%1,624,377CommonSOLE
157085101CERSCERUS CORP$2.4M0.53%1,587,228CommonSOLE
87164F905SYNDAX PHARMACEUTICALS INC$2.3M0.50%172,400CALLSOLE
00370M103ABVXABIVAX SA$2.1M0.46%285,120CommonSOLE
90466Y103UNICYCIVE THERAPEUTICS INC$2.0M0.43%2,486,709CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$1.9M0.42%100,000CommonSOLE
24661P807DCTHDELCATH SYS INC$1.9M0.41%155,325CommonSOLE
N90064101QUREUNIQURE NV$1.8M0.39%100,000CommonSOLE
60785L207MODULAR MED INC$1.7M0.38%1,272,015CommonSOLE
483119202KALAEURKALA BIO INC$1.6M0.35%231,070CommonSOLE
640979900NEUMORA THERAPEUTICS INC.$1.6M0.34%147,200CALLSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$1.4M0.30%233,281CommonSOLE
375558103GILDGILEAD SCIENCES INC$923,7000.20%10,000CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$903,4910.20%121,274CommonSOLE
75041J101RADXRADIOPHARM THERANOSTICS LTD$841,4530.18%187,406CommonSOLE
282559103ETNBGBP89BIO INC$754,7160.17%96,511CommonSOLE
92243A200VXRTVAXART INC$713,5990.16%1,077,782CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$403,0680.09%595,990CommonSOLE
35168W103GUTSFRACTYL HEALTH INC$364,4590.08%176,922CommonSOLE
09077V100BIOABIOAGE LABS INC$231,4490.05%39,974CommonSOLE
77313F114RCKTWROCKET PHARMACEUTICALS INC$3,5960.00%104,828CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.